Galderma Group AG (GALDY)
| Market Cap | 35.21B |
| Revenue (ttm) | 4.44B |
| Net Income (ttm) | 231.00M |
| Shares Out | n/a |
| EPS (ttm) | 0.97 |
| PE Ratio | 152.42 |
| Forward PE | 49.93 |
| Dividend | 0.02 (0.08%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 498 |
| Average Volume | 6,807 |
| Open | 27.82 |
| Previous Close | 27.82 |
| Day's Range | 27.82 - 29.00 |
| 52-Week Range | 15.51 - 29.00 |
| Beta | n/a |
| RSI | 68.32 |
| Earnings Date | Jul 24, 2025 |
About Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic ... [Read more]
Financial Performance
Financial StatementsNews
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of ...
Galderma establishes new U.S. headquarters in Miami and strengthens regional leadership
Strategic move aims to accelerate innovation and growth in the U.S., Galderma's largest region MIAMI , June 17, 2025 /PRNewswire/ -- Galderma (SIX: GALD), the pure-play dermatology category leader, to...